Cara Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021 | New

0

STAMFORD, Connecticut, Nov. 01, 2021 (GLOBE NEWSWIRE) – Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on the development and commercialization of new chemical entities designed to relieve pruritus by selectively targeting kappa opioid receptors devices, today announced that the company will host a live audio conference call and webcast on Monday, November 8, 2021 at 4:30 p.m. ET to present third quarter 2021 financial results and provide a business update.

To join the conference call, please dial (855) 445-2816 (national) or (484) 756-4300 (international) and refer to Conference ID 1480703. A live webcast of the call is available. accessible under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived recording of the webcast will be available on Cara’s website approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel chemical entities designed to relieve pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a proprietary new class of product candidates, led by KORSUVA ™ (CR845 / difelikefalin), a first-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. KORSUVA Injection was approved by the United States Food and Drug Administration (FDA) for the treatment of moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults on hemodialysis on August 23, 2021. Oral KORSUVA a completed phase 2 clinical trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in phase 2 trials in patients with primary biliary cholangitis and notalgia paresthetica with pruritus moderate to severe.

MEDIA CONTACT: Annie Spinetta 6 Degrés 973-768-2170 [email protected]

INVESTOR CONTACT: Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 [email protected]

Copyright 2021 GlobeNewswire, Inc.


Source link

Leave A Reply

Your email address will not be published.